An object of the present invention is to provide a method for analyzing an isomer of triglyceride, a method for sorting oils and fats having different contents of an isomer of triglyceride, and a method for producing triglyceride of which an isomer can be fractionated. The present invention is a method for analyzing triglyceride, including a step of analyzing an isomer of triglyceride by supercritical fluid chromatography, in which multiple types of stationary phases are used in the supercritical liquid chromatography, and at least two stationary phases among the stationary phases have different chiral selectors in each of which one or more chlorines are bound to a polysaccharide derivative.

The novel porous framework materials (such as metal organic frameworks or covalent organic frameworks) having a wide range of applications, which was designed and developed in an inventive manner to resolve issues with respect to a carrier material in a stationary phase of a conventional chiral chromatographic column in which the carrier material has poor stability, a chiral resolving agent has a low loading rate, and the chiral resolving agent is prone to loss or is applied in a restricted manner. The porous framework material efficiently loads a chiral resolving agent (such as proteins, enzymes, or macrocyclic antibiotics) by means of covalent bonding, adsorption, embedding, and crosslinking, such that a variety of efficient and durable chiral stationary phases are prepared to serve as a novel high-performance chromatographic column filler used for chromatographic chiral separation (such as high-performance liquid chromatography or capillary chromatography). The various chiral stationary phases prepared by applying the above technique have high separation efficiency, high stability, and durability, and have been successfully applied to perform efficient separation of different kinds of chiral materials such as chiral amino acids and a chiral drug. The technique greatly widens the application range and extends the service life of a chiral chromatographic separation column.

Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).

A porous chiral material of formula [M(L).sub.1.5(A)].sup.+X.sup. wherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and X.sup. is an anion.

Disclosed is a laevorotatory enantiomer of the configurational stereoisomer of difethialone, named homo-stereoisomer, the formula of which is 3-(4-bromobiphenyl-4-yl)-1-(4-hydroxythiocoumarin-3-yl)-1,2,3,4-tetrahydronaphthalene, in which carbons 1 and 3 of the 1,2,3,4-tetrahydronaphthalene group have the same absolute configuration.

Provided are two-dimensional chromatography systems and methods for separating and/or analyzing complex mixtures of organic compounds. In particularly, a two-dimensional reversed-phase liquid chromatography (RPLC)supercritical fluid chromatography (SFC) system is described including a trapping column at the interface which collects the analytes eluted from the first dimension chromatography while letting the RPLC mobile phase pass through. The peaks of interest from the RPLC dimension column are effectively focused as sharp concentration pulses on the trapping column, which is subsequently injected onto the second dimension SFC column. The system can be used for simultaneous achiral and chiral analysis of pharmaceutical compounds. The first dimension RPLC separation provides the achiral purity result, and the second dimension SFC separation provides the chiral purity result (enantiomeric excess).

The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

A host material may be used for the separation of elements or compounds, wherein the host material is an organic molecular solid with suitable cavities for accommodating a guest material to be separated, and with interconnections between the cavities to allow the guest material to diffuse through the host material, and wherein said interconnections are closed for a proportion of the time or have a static pore limiting diameter which is smaller than the static dimension of the guest material. Applications include separations of rare gases, chiral molecules, and alkanes. One class of suitable host materials may be made by imine condensation.

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.

A porous chiral material of formula [M(L).sub.1.5(A)].sup.+X.sup. wherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and X.sup. is an anion